A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
The study will last about 20 weeks and may include up to 6 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participant must have migraine with or without aura and willing to complete an eDiary
-Participant must have history of disabling migraine for at least 1 year, with migraine onset before the age of 50 years
-Participant must have history of 3 to 8 migraine attacks per month (<15 headache days per month) during the past 3 months
-Participant must not have history of dizziness
-Participant must not have increased risk of having seizures
-Participant must not have diabetes that has caused other serious health problems
-Participant must not have history, within past 12 months, of chronic migraine or other forms of chronic headache disorder
-Participant must not have recently started taking a new migraine preventive medication or have started taking a different dose of a preventive migraine medication
-Participant must not have certain serious infections or medical conditions, including history of drug or alcohol dependence in past year
-Participant must not be pregnant or breastfeeding